Pallas Capital Advisors LLC Invests $298,000 in IQVIA Holdings Inc. (NYSE:IQV)

Pallas Capital Advisors LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, Holdings Channel.com reports. The fund acquired 1,519 shares of the medical research company’s stock, valued at approximately $298,000.

Other large investors also recently made changes to their positions in the company. Nordea Investment Management AB grew its position in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Simplify Asset Management Inc. grew its position in IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after purchasing an additional 3,894 shares in the last quarter. Versor Investments LP bought a new position in IQVIA in the third quarter valued at $1,328,000. JPMorgan Chase & Co. grew its position in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Finally, CIBC Asset Management Inc grew its position in IQVIA by 3.3% in the third quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock valued at $62,501,000 after purchasing an additional 8,490 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of IQVIA stock opened at $196.01 on Thursday. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a 50-day simple moving average of $201.43 and a two-hundred day simple moving average of $221.61. The stock has a market capitalization of $35.58 billion, a price-to-earnings ratio of 25.72, a price-to-earnings-growth ratio of 2.05 and a beta of 1.48.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on IQV shares. The Goldman Sachs Group decreased their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Robert W. Baird decreased their target price on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a research report on Wednesday, December 11th. William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Bank of America cut their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Finally, Redburn Atlantic began coverage on shares of IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 price target for the company. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $255.82.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.